235 related articles for article (PubMed ID: 33996154)
21. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jung ST; Jeon DG
J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296
[TBL] [Abstract][Full Text] [Related]
22. Magnetic resonance imaging is appropriate for determining the osteotomy plane for appendicular osteosarcoma after neoadjuvant chemotherapy.
Han G; Wang Y; Bi WZ; Wang DJ; Lu SB; Zhang L; Zhao B
Med Oncol; 2012 Jun; 29(2):1347-53. PubMed ID: 21350876
[TBL] [Abstract][Full Text] [Related]
23. Correlation between fluid-fluid levels on initial MRI and the response to chemotherapy in stage IIb osteosarcoma.
Jeon DG; Cho WH; Song WS; Kong CB; Cho SH; Lee JW; Lee SY
Ann Surg Oncol; 2014 Jun; 21(6):1956-62. PubMed ID: 24577812
[TBL] [Abstract][Full Text] [Related]
24. Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma.
Cates JMM
Am J Surg Pathol; 2018 Apr; 42(4):485-491. PubMed ID: 29200101
[TBL] [Abstract][Full Text] [Related]
25. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients.
Tunn PU; Reichardt P
Onkologie; 2007 May; 30(5):228-32. PubMed ID: 17460416
[TBL] [Abstract][Full Text] [Related]
27. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
28. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
29. The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.
Tsuda Y; Ogura K; Shinoda Y; Kobayashi H; Tanaka S; Kawai A
BMC Cancer; 2018 May; 18(1):614. PubMed ID: 29855362
[TBL] [Abstract][Full Text] [Related]
30. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
31. [Prediction of chemotherapy response in primary osteosarcoma using the machine learning technique on radiomic data].
Dufau J; Bouhamama A; Leporq B; Malaureille L; Beuf O; Gouin F; Pilleul F; Marec-Berard P
Bull Cancer; 2019 Nov; 106(11):983-999. PubMed ID: 31587802
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients.
Yu W; Sun M; Wang W; Shen Z; Wang Y; Li H
Support Care Cancer; 2024 Jun; 32(7):415. PubMed ID: 38847977
[TBL] [Abstract][Full Text] [Related]
33. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
34. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
[TBL] [Abstract][Full Text] [Related]
35. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
[TBL] [Abstract][Full Text] [Related]
36. Texture analysis for chemotherapy response evaluation in osteosarcoma using MR imaging.
Baidya Kayal E; Kandasamy D; Khare K; Bakhshi S; Sharma R; Mehndiratta A
NMR Biomed; 2021 Feb; 34(2):e4426. PubMed ID: 33078438
[TBL] [Abstract][Full Text] [Related]
37. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy.
Bacci G; Longhi A; Fagioli F; Briccoli A; Versari M; Picci P
Eur J Cancer; 2005 Dec; 41(18):2836-45. PubMed ID: 16298125
[TBL] [Abstract][Full Text] [Related]
39. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience.
Szendroi M; Pápai Z; Koós R; Illés T
J Surg Oncol; 2000 Feb; 73(2):87-94. PubMed ID: 10694644
[TBL] [Abstract][Full Text] [Related]
40. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
